FT516 and IL2 With Enoblituzumab for Ovarian Cancer
Status:
Recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
This is a single center Phase I clinical trial of FT516 administered intraperitoneally (IP)
once a week for 3 consecutive weeks for the treatment of recurrent gynecologic cancers. As
this is an early 1st in human study and the 1st intraperitoneal infusion of FT516, the safety
of FT516 is confirmed prior to adding enoblituzumab as an intravenous infusion approximately
1 week prior to the 1st dose of FT516 and every 3 weeks beginning on Day 22 (1 week after the
last dose of FT516). Each dose of FT516 is followed directly by an IP infusion of
interleukin-2 (IL-2) to facilitate natural killer (NK) cell survival. A short course of
outpatient lymphodepletion chemotherapy is given prior to the 1st dose of FT516.